ProCE Banner Activity


Emerging Agents in AD: Current Evidence


The therapeutic landscape for atopic dermatitis (AD) is expanding rapidly. There are several novel agents available and more on the horizon with proven durable efficacy and favorable safety profiles. Tune in to the second of 3 accredited on-demand Medical Minute modules to learn about new and emerging targeted therapies for managing AD.

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners: 0.50 Nursing contact hours, includes 0.50 hour of pharmacotherapy credit

Released: July 17, 2023

Expiration: July 16, 2024



Victoria Garcia-Albea

Victoria Garcia-Albea, NP, DCNP

Lahey Dermatology Nurse Practitioner Training Program
Lahey Hospital and Medical Center
Burlington, Massachusetts

Benjamin Ungar

Benjamin Ungar, MD

Assistant Professor
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York

Provided by

Provided by Partners for Advancing Clinical Education (PACE)

ProCE Banner


This activity is supported by educational grants from AbbVie Inc, Galderma, and Lilly.

AbbVie Inc.



Target Audience

This program is intended for NPs and PAs managing patients with atopic dermatitis in dermatology and primary care settings.

Program Learning Goal

The goal of this program is to improve knowledge and competency of primary care and dermatology NPs and PAs regarding the mechanisms of action and the latest efficacy and safety data for emerging agents in AD management and apply this knowledge to personalized treatment selection for patients with AD as these agents become available.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Summarize key clinical trial data regarding the efficacy and safety of emerging agents for the treatment of AD

  • Incorporate recent efficacy and safety data on emerging therapies into clinical decisions for patients with AD


Partners for Advancing Clinical Education (PACE) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this education activity:

Primary Author

Victoria Garcia-Albea, NP, DCNP

Lahey Dermatology Nurse Practitioner Training Program
Lahey Hospital and Medical Center
Burlington, Massachusetts

Victoria Garcia-Albea, NP, DCNP, has no relevant financial relationships to disclose.

Benjamin Ungar, MD

Assistant Professor
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York

Benjamin Ungar, MD: consultant/advisor/speaker: Arcutis, Castle Biosciences, Fresenius Kabi, Pfizer, Sanofi; researcher: Incyte, Pfizer, Rapt Therapeutics.

The planners and content peer reviewers from Partners for Advancing Clinical Education and Practicing Clinicians Exchange do not have any relevant financial relationships to disclose except Kristine Kucera as noted below.

Kristine Kucera, PA-C, MPAS, DHSc: consultant/advisor/speaker: AbbVie, Amgen, Beiersdorf, Bristol Myers Squibb, Janssen, LEO Pharma, Novartis, Sun Pharma, UCB.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from July 17, 2023, through July 16, 2024:

  1.  Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

A picture containing logoDescription automatically generated

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


ANCC Credit Designation
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.5 contact hours, including 0.5 hours of pharmacology credit.

AAPA Credit Designation

AAPAPartners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until July 16, 2024. PAs should only claim credit commensurate with the extent of their participation.


IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credits for learning and change.